Prostate Cell News Volume 14.34 | Sep 8 2023

    By
    Bob
    -
    0
    23








    2023-09-08 | PCN 14.34


    Prostate Cell News by STEMCELL Technologies
    Vol. 14.34 – 8 September, 2023
    TOP STORY

    Low-Dose Carboplatin Modifies the Tumor Microenvironment to Augment CAR T Cell Efficacy in Human Prostate Cancer Models

    The authors assessed the efficacy of Lewis Y antigen-specific chimeric antigen receptor (CAR) T cells in patient-derived xenograft models of prostate cancer.
    [Nature Communications]

    Full Article
    Access scientific and product support from STEMCELL Technologies
    PUBLICATIONSRanked by the impact factor of the journal

    Targeting the Metabolic Enzyme PGAM2 Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting BCL2 Signaling

    Scientists found that targeting a glycolytic enzyme, phosphoglycerate mutase PGAM2, significantly enhanced the sensitivity of enzalutamide (ENZ)-resistant prostate cancer cells to ENZ both in vivo and in vitro.
    [Cancer Research]

    Abstract

    Targeting Hyaluronan-Mediated Motility Receptor (HMMR) Enhances Response to Androgen Receptor Signaling Inhibitors in Prostate Cancer

    The authors identified the hyaluronan-mediated motility receptor as a survival factor in prostate cancer and investigated its potential as a co-target for overcoming resistance to androgen receptor signaling inhibitors.
    [British Journal of Cancer]

    Full Article

    FOXP2 Confers Oncogenic Effects in Prostate Cancer

    Scientists found that FOXP2 was overexpressed in human prostate cancer cells and prostate tumors, but its expression was absent in normal prostate epithelial cells and low in benign prostatic hyperplasia.
    [eLife]

    Abstract

    Inhibition of Integrin Receptors Reduces Extracellular Matrix Levels, Ameliorating Benign Prostate Hyperplasia

    Investigators found global succinylation level was higher in benign prostate hyperplasia compared with healthy prostate tissues.
    [International Journal of Biological Macromolecules]

    Abstract

    Knockdown of KIF15 Suppresses Proliferation of Prostate Cancer Cells and Induces Apoptosis through PI3K/Akt Signaling Pathway

    Researchers explored the significance and role of kinesin Family member 15 (KIF15) in prostate cancer and showed some potential value for prostate cancer.
    [Cell Death Discovery]

    Full Article

    Discovery of Novel Flavonoid-Based CDK9 Degraders for Prostate Cancer Treatment via a PROTAC Strategy

    Scientists presented findings that demonstrated the potential of CP-07 as a powerful flavonoid-based CDK9 degrader for prostate cancer therapy.
    [European Journal Of Medicinal Chemistry]

    AbstractGraphical Abstract

    Exosomal miR-222-3p Contributes to Castration-Resistant Prostate Cancer by Activating mTOR Signaling

    Investigators found that miR-222-3p was elevated in androgen-independent prostate cancer cells, which resulted in remarkable enhancement of cell proliferation, migration, and invasion ability.
    [Cancer Science]

    Full Article

    Icariin-Curcumol Promotes Docetaxel Sensitivity in Prostate Cancer through Modulation of the PI3K-Akt Signaling Pathway and the Warburg Effect

    Researchers determined whether Epimedium brevicornu and Curcuma zedoaria extracts, especially icariin-curcumol, attenuated docetaxek resistance and explored their potential mechanisms in prostate cancer.
    [Cancer Cell International]

    Full Article
    As a scientist, how you separate the facts from the claims is just as important as how you separate your cells. See for yourself.
    REVIEWS

    Emerging Role of miRNA in Prostate Cancer: A Future Era of Diagnostic and Therapeutics

    The authors provide a connection between miRNA expression profiles and prostate cancer by elucidating the fundamental processes of miRNA expression and the target genes.
    [Gene]

    Abstract
    INDUSTRY AND POLICY NEWS

    UK Finally Rejoins Horizon Europe Research Funding Scheme

    The UK government announced that it will rejoin the European Union’s €95 billion research funding program known as Horizon Europe.
    [ScienceInsider]

    Press Release

    Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-Mutant and Other HRD+ Cancers

    Tango Therapeutics, Inc. announced that the US FDA has cleared the Company’s Investigational New Drug application for TNG348, a novel inhibitor of ubiquitin-specific protease 1 (USP1), for the treatment of BRCA1/2 mutant and other homologous recombination deficient (HRD+) cancers.
    [Tango Therapeutics, Inc.]

    Press Release
    FEATURED EVENT

    ESMO Congress 2023

    October 20 – 24, 2023
    Madrid, Spain

    > See All Events

    JOB OPPORTUNITIES

    Faculty Positions – Cancer Metastasis

    The Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States

    Research Assistant – Epigenetics & Molecular Carcinogenesis

    University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Postdoctoral Scientist – Cancer Research Cluster

    Cedars-Sinai – Los Angeles, California, United States

    Postdoctoral Research Fellow – Prostate Cancer

    Cedars-Sinai – Los Angeles, California, United States

    Research Fellow – Genito-Urinary Cancers

    University of South Australia – Adelaide, Australia

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter